General Information
|
|
Product
|
Apelin Peptide
|
Verified Applications
|
Immunodepletion, Immunocompetition
|
Peptide Description
|
Synthetic peptide taken within amino acid region 25-77 on human Apelin protein.
|
Accession #
|
NCBI: NP_059109
|
Physical Properties
|
|
Quantity
|
250 µg
|
Volume
|
100 µl
|
Form
|
Antigenic Blocking Peptide
|
Storage
|
-20⁰C for long term storage
|
Application Protocol
|
Competition/Depletion assay
|
Refer to competition assay protocol
|
Protein
|
Uniprot #
|
Q9ULZ1
|
Overview
|
Endogenous ligand for APJ, an alternative coreceptor with CD4 for HIV-1 infection. Inhibits HIV-1 entry in cells coexpressing CD4 and APJ. Apelin-36 has a greater inhibitory activity on HIV infection than other synthetic apelin derivatives. The oral intake in the colostrum and the milk could have a role in the modulation of the immune responses in neonates. May also have a role in the central control of body fluid homeostasis by influencing AVP release and drinking behavior.
|
Molecular Function
|
G-protein coupled receptor binding, receptor binding
|
Subcellular Location
|
Secreted
|
Expression
|
Expressed in the brain with highest levels in the frontal cortex, thalamus, hypothalamus and midbrain. Secreted by the mammary gland into the colostrum and the milk.
|
Structure
|
Belongs to the apelin family.
|
Alternative Nomenclature
|
AGTRL1 ligand antibody
APEL antibody
Apelin-13 antibody
APJ endogenous ligand antibody
Apln antibody
XNPEP2 antibody
|
|
|